PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett Syndrome
November 01, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
TORONTO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on developing and...
PharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson’s Disease
October 05, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
Grant of US patent strengthens the PharmaTher’s intellectual property portfolio covering novel uses and delivery forms of ketamine Announced positive efficacy and safety data from Phase 1/2 clinical...
PharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May 31, 2022
September 29, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
Nearly $12 million in cash and investment Fully funded for the Company’s development programs, including ketamine injection and infusion products, ketamine microneedle patch and ketamine...
PharmaTher Announces Late-Breaking Abstract Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease at the MDS International Congress of Parkinson's Disease and Movement Disorders®
September 16, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
Ketamine was safe, well-tolerated with 100% of patients treated with ketamine demonstrating reduction in dyskinesias as measured by the Unified Dyskinesia Rating Scale (UDysRS) UDysRS showed a 51%...
PharmaTher Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with KETARX™ Ketamine Patch
September 07, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
KETARX™ Ketamine Patch demonstrated extended delivery of ketamine over 40 hours KETARX™ Ketamine Patch offers flexible dosing through increased size, drug load or concentration of ketamine to better...
PharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine for the Potential Treatment of Parkinson’s Disease and Motor Disorders
July 13, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
TORONTO, July 13, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, announced today that...
PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch
June 29, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
Successfully delivered ketamine and KETABET™ (ketamine and betaine) via microneedle patch, unlocking the potential for desired dosage forms and pharmacokinetic profiles Pursuing Phase 2 clinical...
PharmaTher Announces Positive Results from Study of KETABET™ for Depression
June 07, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
KETABET™ (Ketamine and Betaine) shown effectiveness as measured by the Clinician Administered Dissociative States Scale Study results are adequate to give an effect size in powering a...
PharmaTher To Develop and Commercialize Novel Wearable Ketamine Delivery Device in Collaboration with CCBIO
May 25, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
Wearable ketamine delivery device complements PharmaTher’s ketamine product portfolio, including injectable, intravenous, and microneedle patch PharmaTher aims to become a leader in specialty...
PharmaTher Announces Grant of U.S. Patent on Formulation and Production Process of Ketamine and Ketamine Analogs
May 05, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
TORONTO, May 05, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce...